A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Withdrawn before enrolling · Phase 3

Conditions studied: Peripheral T-Cell Lymphoma

In brief

The purpose of this study is to evaluate whether treatment of E7777 in combination with CHOP has superior efficacy compared with CHOP alone in improving complete response rate (CRR) in first line treatment of subjects with Peripheral T-cell Lymphoma (PTCL).

Key facts

Study ID

NCT01355783

Run by

Eisai Inc.

People needed

0

Starts

2011-03-01

Expected to finish

2014-11-01

Last updated by the study team

2013-11-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Skokie, Illinois, United States
• Study site — Morristown, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.